Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Series of Adenosine Analogs as the First Efficacious Anti‐SARS‐CoV‐2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research Study

8 Dec 2022

Abstract excerpt

Abstract Given the rapid progression of the coronavirus disease 2019 (COVID‐19) pandemic, an ultrafast response was urgently required to handle this major public crisis. To contain the pandemic, investments are required to develop diagnostic tests, prophylactic vaccines, and novel therapies. Lately, nucleoside analog (NA) antivirals topped the scene as top options for the treatment of COVID‐19 caused by the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36718467
DOI: 10.1002/slct.202201912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Series of Adenosine Analogs as the First Efficacious Anti‐SARS‐CoV‐2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research StudyPMID 36718467Read ↗

The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variantsSemantic proximity Read ↗

Nucleotide and nucleoside-based drugs: past, present, and futureSemantic proximity Read ↗

SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19Semantic proximity Read ↗

RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic targetSemantic proximity Read ↗

Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRpSemantic proximity Read ↗

Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In VitroSemantic proximity Read ↗

Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymeraseSemantic proximity Read ↗

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 DrugsSemantic proximity Read ↗

Broad-Spectrum Antiviral Strategies and Nucleoside AnaloguesSemantic proximity Read ↗

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 DrugsSemantic proximity Read ↗

Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2Semantic proximity Read ↗

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.